FDA puts hold on GenVec TNFerade
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GenVec's gene-based oncologicTNFerade is on clinical hold after a possible increased risk of blood clots is seen in interim results of a Phase II esophageal cancer study. In the 24-patient trial, three of eight patients receiving the highest dose developed pulmonary embolism, one of whom died. Investigators judged the death "possibly related to TNFerade and underlying disease." The interim data were presented Oct. 1 at the European Organization for Research & Treatment of Cancer meeting in Geneva, Switzerland. GenVec plans to provide FDA with additional data, the firm said Oct. 7. In addition to esophageal cancer, GenVec's Phase II TNFerade program is looking at locally advanced pancreatic and rectal cancers...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.